Results 291 to 300 of about 1,334,045 (336)

SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher, Dominika Stastna, Ingrid Menkyova, Vaclav Capek, Jiri Lindner, Petra Nytrova, Jan Krasensky, Eliza Varju, Miguel D'haeseleer, Eva Kubala Havrdova, Dana Horakova, Manuela Vaneckova, Niels Bergsland   +12 more
wiley   +1 more source

Reliability of pre-admission patient-reported outcome measures postoperatively assessed via proxies: a prospective, multicenter observational study. [PDF]

Crit Care
Grunow JJ, Hartmann L, Ulm B, Maechler M, Blobner M, Seidenspinner K, Schoennagel L, Weber-Carstens S, Fuest K, Wollersheim T, Schaller SJ.   +10 more
europepmc   +1 more source

Phenotyping Healthcare Use 2–3 Decades Before the First Multiple Sclerosis Demyelinating Event

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Phenotype hospital, physician, and emergency department (ED) visits by diagnoses and specialty up to 29 years pre‐multiple sclerosis (MS) onset versus a matched population without MS. Methods We identified people with MS (PwMS) using population‐based administrative data from Ontario, Canada (1991–2020).
Helen Tremlett, Karl Everett, Colleen J. Maxwell, Feng Zhu, Ayesha Asaf, Ping Li, Kyla A. McKay, Yinshan Zhao, Ruth Ann Marrie   +8 more
wiley   +1 more source

Assessment of current patient reported outcome measures for three core outcome domains for single-sided deafness device intervention trials. [PDF]

J Patient Rep Outcomes
Katiri R, Hall DA, Hoare DJ, Smith S, Adams B, Fackrell K, Horobin A, Hogan N, Buggy N, Kitterick PT.   +9 more
europepmc   +1 more source

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for ...
Fortunata Carbone, Alessandra Colamatteo, Teresa Micillo, Gianmarco Abbadessa, Silvia Garavelli, Clorinda Fusco, Claudia Russo, Francesco Perna, Federica Garziano, Claudia La Rocca, Maria Mottola, Giorgia Teresa Maniscalco, Simona Bonavita, Antonio Luca Spiezia, Alessia Castiello, Roberta Lanzillo, Vincenzo Brescia Morra, Claudio Procaccini, Paola de Candia, Giuseppe Matarese   +19 more
wiley   +1 more source

Detecting rs‐fMRI Networks in Disorders of Consciousness: Improving Clinical Interpretability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Preserved resting‐state functional MRI (rs‐fMRI) networks are typically observed in Disorders of Consciousness (DOC). Despite the widespread use of rs‐fMRI in DOC, a systematic assessment of networks is needed to improve the interpretability of data in clinical practice.
Jean Paul Medina Carrion, Mario Stanziano, Ludovico D'Incerti, Davide Sattin, Stefania Ferraro, Davide Rossi Sebastiano, Francesca Giulia Magnani, Alice Deruti, Davide Fedeli, Ludovico Minati, Francesca Epifani, Marina Grisoli, Matilde Leonardi, Maria Grazia Bruzzone, Anna Nigri, Cristina Rosazza   +15 more
wiley   +1 more source

Electronic Implementation of Patient-Reported Outcome Measures in Primary Health Care: Mixed Methods Systematic Review.

J Med Internet Res
Sasseville M, Supper W, Gartner JB, Layani G, Amil S, Sheffield P, Gagnon MP, Hudon C, Lambert S, Attisso E, Ouellet S, Breton M, Poitras ME, Roux-Lévy PH, Plaisimond J, Bergeron F, Ashcroft R, Wong ST, Groulx A, Paquette JS, D'Anjou N, Langlois S, LeBlanc A.   +22 more
europepmc   +1 more source

Collection of Patient-Reported Outcome Measures in Rural and Underserved Populations. [PDF]

Appl Clin Inform
Cheville A, Patil CL, Boyd AD, Crofford LJ, Dailey D, Martelly V, Fiol GD, Ezenwa MO, Faurot KR, Knisely M, McLeod KR, Morone NE, O'Brien E, Gonzalez-Guarda RM, Sluka KA, Staman K, Thackeray A, Zigler CK, Schlaeger JM.   +18 more
europepmc   +1 more source

Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan, María A. Piedrabuena, María A. Zarate, Sofía Rodríguez Murúa, Ezequiel I. Surace, Mauricio F. Farez, Marcela P. Fiol, María C. Ysrraelit, Jorge Correale   +8 more
wiley   +1 more source

Systematic review on the measurement properties of patient-reported outcome measures (PROMs) for measuring well-being in young children. [PDF]

BMJ Open
Morato-Espino PG, Ramos JMR, Gomez IN.
europepmc   +1 more source